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Abstract 
Hereditary hemorrhagic telangiectasia is characterized by mucocutaneous and visceral 
telangiectasia and involves several organs with vascular malformations. It is an 
autosomal dominant disease and is distinguished into three types, which are due to 
mutations in different genes. The common symptom is anemia, causing a continous need 
of blood transfusion. Depending on the severity and disease manifestation, there are 
various forms of therapy ranging from local therapy activities to operations or drug 
therapy. Here we describe a dramatic improvement of a patient with a high transfusion 
frequency due to severe recurrent anemia successively treated with thalidomide and 
bevacizumab. 
 
Introduction 
Hereditary hemorrhagic telangiectasia (HHT) or Osler-Weber-Rendu syndrome is 
inherited as an autosomal dominant trait, and has a general prevalence of 1/10,000 in 
Caucasians and a prevalence as high as 1/400 in Dutch Antillean people [1]. HHT is 
characterized by widespread telangiectases that can involve the skin, mucous membranes, 
lung, brain, the gastrointestinal tract and/or liver [2]. The telangiectasia is the 
characteristic lesion of HHT. It arises from a dilated post capillary venule that enlarges 
and fuses with an arteriole bypassing the capillary system and resulting in an 
arteriovenous communication [1]. It can present as discrete arteriovenous malformations 
(AVMs) or as multiple diffuse telangiectases.  
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The clinical diagnosis of HHT is based on the presence of at least three of four main 
clinical features: epistaxis, cutaneous or mucosal telangiectases, visceral involvement and 
a family history of HHT [3]. AVMs also occur in internal organs, especially in the lungs 
(in about 33% of patients), in the gastrointestinal tract (in about 44%) and in the liver (in 
around 17%). Up to 15% of the patients are also diagnosed with cerebral involvement [4–
6]. Through the pulmonary AVM, the filtering effect of the pulmonary capillaries is 
restricted. Bacteria and clots can pass through the lungs and subsequently lead to cerebral 
abscesses and emboli. Gastrointestinal bleeding usually begins in the fifth decade of life, 
makes frequent blood transfusions necessary and may in some cases even lead to the 
death of the patient [7]. The liver is commonly affected by vascular malformations that 
may produce portovenous (portal vein to hepatic vein), arteriovenous (hepatic artery to 
hepatic vein), and arterioportal (hepatic artery to portal vein) shunting [2]. Although 
hepatic involvement is often asymptomatic, the commonest clinical manifestation is high-
output cardiac failure secondary to intrahepatic shunting leading to breathlessness and 
fluid retention. Ascites and variceal bleeding are presented as a result of portal 
hypertension by arterioportal shunting, whereas arteriovenous shunting can cause biliary 
ischemia with subsequent necrosis and sclerosing cholangitis [8]. Cerebral and spinal 
malformations may present with seizures, hemorrhage, headaches and neurological 
deficits [9]. 
HHT is caused by mutations in one of two genes that have led to its subclassification 
into types 1 and 2. Type 2 HHT is more frequent. Both genes encode for transmembrane 
proteins involved in the transforming growth factor (TGF)-β signalling pathway and are 
expressed predominantly on vascular endothelium [2]. For HHT type 1, a mutation in the 
endoglin gene on chromosome 9q34 is responsible [10] and for HHT type 2 a mutation in 
the gene for the activin receptor-like kinase 1 (ALK-1) on chromosome 12q13 [11]. 
Additionally, a HHT type 3 has been described in a family with HHT and pulmonary 
involvement due to endoglin, ALK-1 and Smad4 mutations. In this family, a previously 
unidentified disease gene was identified on chromosome 5 [12]. 
Sadick et al. [13] showed increased plasma levels of vascular endothelial growth factor 
and TGF-β in patients with HHT. Thalidomide, originally used to treat nausea in 
pregnancy in the early 1960s, was removed from the market when severe congenital 
defects became evident in newborns, a result of its antiangiogenic activity that reduced 
the blood supply to fetal organs and tissues at specific times of development [14, 15]. 
However, thalidomide has enjoyed a renaissance in recent years. Under strict guidelines 
and carefully controlled inclusion criteria, it is now used to treat various pathologies: it 
reportedly inhibits bleeding in individuals with certain gastrointestinal diseases [16–19] 
and in HHT patients who received thalidomide as an antiangiogenic cancer therapy [20, 
21]. The mechanisms by which thalidomide inhibits bleeding from vascular 
malformations are unknown, although it has been reported to regulate the expression of 
components of signaling pathways that are involved in stimulating or inhibiting 
angiogenesis, such as the VEGF pathway [22]. More recently, it has been shown to target 
endothelial tip cells of immature vessels [15]. 
Several case reports have been published on HHT patients who were treated with 
bevacizumab only [23–27]. We present a case of a patient with severe HHT first treated 
with thalidomide and subsequently with bevacizumab.   
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Case Report 
A 59-year-old man with a history of HHT for 20 years first presented to our hospital in 1998 (fig. 1). 
He had been smoking for several years and had developed a chronic obstructive pulmonary disease. He 
had taken tiotropium bromide and beclometasone dipropionate as a dose inhaler for some years. Iron 
substitution had been performed for several years. Multiple angiodysplasias of the gastrointestinal tract 
were diagnosed by endoscopic investigations. These angiodysplasias were localised primarily in the 
corpus ventriculi, duodenum and jejunum (fig. 2). Several endoscopic interventions were performed, 
such as argon beamer coagulation. But the frequency of required blood transfusions was not reduced 
significantly by these interventions. In February 2005, an AVM in the right lower lung was discovered. 
A right heart catheter investigation measured a shunt flow of 16% of the cardiac output. In the same 
session, the shunt was occluded. Hypothyroidism was diagnosed in 2007. Since then the patient had 
been treated with thyroxine. Starting from 2004, the patient developed multiple antibodies and cold 
agglutinins. Therefore, the procurement of appropriate erythrocyte concentrates is very difficult. To 
achieve a reduction of the transfusion frequency, we first started a thalidomide therapy (200 mg/day) in 
March 2005. As fig. 3 and fig. 4 show, the frequency of transfusions could be reduced markedly under 
thalidomide therapy. This therapy was continued until August 2007, when it had to be discontinued 
because of deterioration of lung function. After termination of the thalidomide therapy, a slight increase 
of the frequency of required transfusions was noticeable. Therefore, in May 2008, we decided to begin a 
therapy with the monoclonal human antibody bevacizumab (fig. 3, 4). From the start of therapy with 
bevacizumab until June 2010, the patient needed only 43 erythrocyte concentrates. Under thalidomide 
therapy, 183 had been necessary and before these two therapies the patient had received 700 erythrocyte 
concentrates from April 1998 to March 2005 (fig. 3).  
Starting from April 1998, the patient has received erythrocyte concentrates in our clinic only. Since 
then he has received a total of 958 erythrocytes concentrates. Before 1998 we cannot specify the number 
of received erythrocyte concentrates, because he had been treated in various hospitals. 
The serology for hepatitis B, C and human immunodeficiency virus is fortunately negative. 
Discussion 
Patients with HHT had so far been treated only with blood transfusions. In patients 
with epistaxis, multiple approaches have been tried, including electrocautery, laser, 
septodermoplasty, embolization, arterial ligation, and, most recently, sprayable fibrin 
sealant [28, 29]. All of these approaches are largely palliative with variable results, many 
requiring repeated interventions, except for nasal closure [30].  
In HHT patients with gastrointestinal bleeding, numerous endoscopic examinations or 
surgical resections are performed to prevent recurrent bleeding. However, these are also 
palliative approaches. In addition, these patients must receive erythrocyte concentrates 
and iron substitution. Gastrointestinal bleeding in HHT patients could be reduced by 
administration of an estrogen-progesterone combination [31]. This therapy has the 
advantage that the gastrointestinal sections are treated, which cannot be examined 
endoscopically. In a study by van Cutsem et al. [32] in several HHT patients with 
gastrointestinal bleeding the number of required blood transfusions could be reduced 
after hormone treatment. This therapy, however, is problematic for male patients because 
the side effects (such as gynecomastia, edema, and feminization) are often very 
pronounced. Therefore, the hormone therapy is actually reserved to postmenopausal 
women who have undergone hysterectomy. 
In recent years, the process of catheter embolization for pulmonary AVMs has been 
enforced. The enlarged vessels are closed using coils, sometimes supplemented by small  
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balloons. Despite the success of this treatment, remaining AVMs are diagnosed in up to 
60% of the patients [33]. 
Currently, treatment of patients with hepatic HHT with liver transplantation is 
curative but involves a risk of acute mortality as well as problems of long-term 
immunosuppression. Hepatic arterial embolization or occlusion is associated with 
significant morbidity and mortality and is not recommended outside palliative 
circumstances [2, 34]. Recommendations for therapy of cerebral AVMs are not available. 
Our patient was treated for recurrent anemia with transfusions until March 2005. The 
thalidomide therapy halved the number of transfusions. As after thalidomide therapy the 
frequency of blood transfusion units increased, a therapy with bevacizumab was started. 
The therapy with bevacizumab caused a dramatic reduction of the number of required 
transfusions. In these two years, only 43 erythrocyte concentrates were administered. 
Impressive as these data may be, one must also be careful because bevacizumab has 
also a nonnegligible toxicity. In fact, it may induce cardiac failure, hemorrhage, arterial 
thromboembolic events, hypertensive crisis, nephritic syndrome and wound-healing.  
Although multiple drugs have been evaluated, there is currently no randomized 
controlled trial confirming efficacy for preventing bleeding from vascular malformations. 
Therefore, an effective medical treatment for these patients is urgently needed. A clinical 
trail with bevacizumab for patients with severe HHT is warranted. 
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Fig. 1. Images of the patient with multiple HHT of the skin. 
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Fig. 2. Enteroscopy image of the patient. These images show the jejunum at 150 cm aboral. There are 
multiple angiodysplasias (arrows) without macroscopically visible bleeding. 
 
 
 
Fig. 3. The number of erythrocyte concentrate (EC) transfusions per year from April 1998 till June 
2010. 
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Fig. 4. The number of erythrocyte concentrate (EC) transfusions per month from April 1998 till June 
2010. 
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